Emergent Biosolutions
EBS
168 hedge funds and large institutions have $728M invested in Emergent Biosolutions in 2014 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 57 increasing their positions, 50 reducing their positions, and 9 closing their positions.
389% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 9
26% more funds holding
Funds holding: 133 → 168 (+35)
26% more capital invested
Capital invested by funds: $579M → $728M (+$148M)
14% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 50
9.04% more ownership
Funds ownership: 69.27% → 78.3% (+9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$18.5M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$10.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10.7M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$10.5M |
| 5 |
GAM
Gotham Asset Management
New York
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$25.1M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$12.9M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$7.3M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$4.75M |
| 5 |
AI
Ariel Investments
Chicago,
Illinois
|
-$2.82M |
EBS Hedge Fund Activity: Q1 2014 in Review
168 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2014, worth a combined $728M — up 26% from $579M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new EBS positions and 9 closed out — a net gain of 35 holders — while 57 added to existing stakes and 50 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $18.5M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $25.1M sold.
- 168 institutional investors held Emergent Biosolutions (EBS) as of Q1 2014, up from 133 in Q4 2013.
- Funds reported $728M of Emergent Biosolutions stock for Q1 2014, up 26% quarter-over-quarter.
- 44 funds opened new Emergent Biosolutions positions in Q1 2014 and 9 closed out, a net change of +35 holders.
- The largest Emergent Biosolutions buyer in Q1 2014 was Broadfin Capital, an estimated $18.5M added.
- The largest Emergent Biosolutions seller in Q1 2014 was Consonance Capital Management, an estimated $25.1M sold.
Based on aggregated 13F filings for Q1 2014.